Media headlines about GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5190765929276 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Howe & Rusling Has Increased Its Microsoft (MSFT) Position by $1.19 Million; Highland Capital Management LP Has … – Hill Country Times (hillcountrytimes.com)
- Sabby Management Boosted Gw Pharmaceuticals Plc (GWPH) Position by $1.29 Million; Pra Group (PRAA … – Hill Country Times (hillcountrytimes.com)
- What's Behind This Marijuana Stock Soaring 81.5% in December? (finance.yahoo.com)
- Tracking Technical Indicators on GW Pharmaceuticals plc (GWPH) – Wall Street Morning (wallstreetmorning.com)
- Epidiolex Approval Does Not Make GW Pharmaceuticals A Buy – Seeking Alpha (seekingalpha.com)
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $131.32 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. The stock has a market cap of $3,330.00, a P/E ratio of -18.60 and a beta of 2.65. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $140.52.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/10/gw-pharmaceuticals-plc-gwph-receives-daily-news-sentiment-rating-of-0-08.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.